Gulf Pharmaceutical Industries, Julphar, has reported that the company generated AED169.7 million in sales representing a 90 percent increase in comparison to Q2 2019, owing to the lift of the temporary suspension on export of products to Kuwait, Saudi Arabia, Oman and Bahrain earlier this year and growth in several of its core markets.
The announcement came as a part of its financial results for the second quarter of 2020. In July, Julphar successfully restructured its capital base following the completion of the rights issue which was oversubscribed by 2.3 times indicating strong investor confidence.
Sheikh Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said, “It is deeply encouraging to witness the improvement in sales and reduction of losses over the last quarter, which is testament to the resilience of the company’s business model and exemplary vision. The progress we have achieved is instrumental to sustain our 40-year legacy of providing advanced healthcare solutions globally.”
Dr. Essam Farouk, Chief Executive Officer of Julphar, said, “Following the successful capital restructuring and the return to Saudi Arabia and all GCC markets, we are progressing on plan towards achieving profitability and to further enhance our business performance. By maintaining the course in our transformation, we continue our mission to offer full disease management to the millions of people that we proudly serve locally, regionally, and globally.”
In 2020, Julphar announced the relaunch of over 80 products in Saudi Arabia, Kuwait, Bahrain, and Oman after the confirmation of its full compliance with Good Manufacturing Practices, GMP, through an inspection conducted by the Gulf Health Council, GHC, and the Saudi Food and Drug Authority.
The future plans of Julphar focus on the strategic areas of the business as the company divests from non-core subsidiaries, regains market position in Saudi Arabia, Kuwait and Oman, continues to build new alliances and partnerships to strengthen the company’s product portfolio, launch new products in core therapeutic areas and invest in capital expenditure to improve operations efficiency.
Also Read: ‘Julphar’ pushes its capital restructuring plan
Also Read: Russia registers first ever COVID-19 vaccine
